GLP-1 drugs prove they protect the heart
New CapabilitiesReal-world data and a large trial show tirzepatide lowers heart attacks, strokes, and cardiovascular death in diabetes patients
2 days ago: Real-world data confirm the benefitNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
About 53,000 Americans with type 2 diabetes and heart disease were tracked through their insurance records. Those who started tirzepatide had a 2.9% risk of a heart attack, stroke, or cardiovascular death within a year, against 4.4% for a comparison drug.
Tirzepatide is sold as Mounjaro for diabetes and Zepbound for weight loss. The Harvard study, published in The BMJ, backs up a large randomized trial from December: a drug taken for blood sugar and weight also guards the heart.
Why it matters
Heart disease is the top killer of people with type 2 diabetes, and drugs millions already take for weight and blood sugar now cut that risk too.
Questions about this story
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Timeline
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Sign up to save your score and track a streak across stories.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
The Indianapolis drugmaker that developed tirzepatide, a dual GIP and GLP-1 receptor agonist.
The Danish drugmaker whose semaglutide first won an FDA heart-protection label among these drugs.
The federal agency that decides which health claims a drug's label can carry.
Timeline
June 2016 August 2026
-
Real-world data confirm the benefit
Latest StudyA Harvard analysis in The BMJ finds tirzepatide users had a 2.9% one-year heart-event risk versus 4.4% on sitagliptin.
-
SURPASS-CVOT published
Clinical TrialTirzepatide matches dulaglutide on heart events and lowers all-cause deaths by 16% across 13,165 patients in 30 countries.
-
FDA approves a heart claim
RegulatoryThe FDA clears semaglutide (Wegovy) to reduce cardiovascular risk, the first of these drugs to earn the label.
-
SELECT trial changes the picture
Clinical TrialSemaglutide cuts major heart events by 20% in overweight or obese patients with heart disease and no diabetes.
-
First GLP-1 heart benefit
Clinical TrialThe LEADER trial shows liraglutide (Victoza) cuts heart events in diabetes patients, the first GLP-1 drug to do so.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Rosiglitazone safety scare (2007)
Cardiologist Steven Nissen published a meta-analysis linking the diabetes pill rosiglitazone (Avandia) to a 43% higher risk of heart attack. Prescriptions and sales fell sharply.
The FDA added strong warnings and heavily restricted the drug's use.
In 2008 the FDA began requiring new diabetes drugs to prove they do not raise heart risk, making the cardiovascular outcome trial a standard hurdle.
That mandate is why tirzepatide was tested against the heart at all. A rule meant to catch harm now surfaces benefit.
EMPA-REG OUTCOME trial (2015)
A trial of the diabetes drug empagliflozin in 7,020 patients found it cut death from cardiovascular causes by 38%, a result few expected from a blood-sugar drug.
Guidelines moved SGLT2 inhibitors toward the front line for diabetes patients with heart disease.
It reset expectations, showing a diabetes drug could actively protect the heart rather than merely avoid harm.
Tirzepatide follows the same path from metabolic drug to heart drug, changing how doctors pick diabetes treatments.
Scandinavian Simvastatin Survival Study (1994)
The 4S trial followed 4,444 heart patients and found simvastatin cut deaths by 30%, proving cholesterol drugs prevent heart attacks.
Statins became standard care for people with heart disease.
It made long-term preventive medication routine for hundreds of millions of people.
GLP-1 drugs may trace the statin arc: a drug class that starts targeted and ends up widely prescribed to prevent heart events.
